Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer

Anti-EGFR antibodies such as cetuximab are active against KRAS/NRAS wild-type colorectal cancers (CRC) but acquired resistance invariably evolves. Which mutational mechanisms enable resistance evolution and whether adaptive mutagenesis, a transient cetuximab-induced increase in mutation generation,...

Descripción completa

Detalles Bibliográficos
Autores principales: Woolston, Andrew, Barber, Louise J, Griffiths, Beatrice, Pich, Oriol, Lopez-Bigas, Nuria, Matthews, Nik, Rao, Sheela, Watkins, David, Chau, Ian, Starling, Naureen, Cunningham, David, Gerlinger, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7611134/
https://www.ncbi.nlm.nih.gov/pubmed/34017094
http://dx.doi.org/10.1038/s41559-021-01470-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7611134/
https://www.ncbi.nlm.nih.gov/pubmed/34017094
http://dx.doi.org/10.1038/s41559-021-01470-8

Ejemplares similares